Nektar (NKTR) Q2 Revenue Falls 52%
Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biopharmaceutical company focusing on immunology and oncology drug development, reported its latest financial results on August 7, 2025, for the second quarter of 2025. The most significant news was that both non-GAAP earnings per share (EPS) and GAAP revenue came in ahead of estimates, with GAAP revenue totaling $11.2 million compared to the $9.49 million estimate. However, revenue (GAAP) declined sharply from the prior year as product sales disappeared following the sale of the company's manufacturing facility. The period also brought important clinical milestones, most notably a regulatory Fast Track designation from the U.S. Food and Drug Administration (FDA) for rezpegaldesleukin in alopecia areata. While operational losses remain substantial, a mid-year public stock offering extended the cash runway into the first quarter of 2027. Overall, the quarter was marked by encouraging pipeline progress but also highlighted a business still in transition and heavily reliant on future clinical and partnership milestones.
Source: Analyst estimates for the quarter provided by FactSet.
Nektar Therapeutics develops immunology and oncology drug candidates designed to modulate the immune system. Its most advanced asset is rezpegaldesleukin, a biologic therapy aimed at boosting regulatory T cell function to treat autoimmune diseases like atopic dermatitis and alopecia areata. The pipeline also includes NKTR-255, an interleukin-15 receptor agonist for cancer treatment, currently progressing through investigator-led and partnered studies.
Source Fool.com
